ArticleBMC ophthalmology2026
Clinical and imaging features of SMACH.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
background/obejectivesTo describe clinical and multimodal imaging features of patients with stellate multiform amelanotic choroidopathy (SMACH). SUBJECTS/
methodsThis retrospective multicenter study included patients with SMACH at Severance Eye Hospital and Seoul National University Bundang Hospital from January 2005 to October 2024.
resultsThe mean age of SMACH at initial diagnosis was 30.48 ± 22.52 years from 8 eyes of 8 patients. The cohort comprised 3 males and 5 females. Fluorescein angiography (FA) demonstrated a core filled with angiomatous vessels accompanied by mild leakage, irrespective of the presence of subretinal fluid (SRF). Indocyanine green angiography (ICGA) revealed prominent filling defects corresponding to the choroidal lesions, and near‑infrared reflectance imaging further showed marked hyperreflectivity along the surface of the dendritic mass lesions, which distinctly highlighted the stellate configuration of the tumors. Three patients (3/8) had SRF. Whether treated or not, the SRF was almost completely absorbed, and visual acuity fully recovered. Most patients with SMACH maintained good visual acuity above 0.1 (logMAR).
conclusionsIn patients with SMACH, typical findings in FA and ICGA are presented to facilitate differentiation from other diseases. Understanding the disease entities and favorable prognosis of SMACH should aid clinicians in differentiating these lesions from other tumor diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.